# A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

> **NCT05012618** · PHASE1 · TERMINATED · sponsor: **Chugai Pharmaceutical** · enrollment: 128 (actual)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** LUNA18
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05012618
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-08
- **Primary completion:** 2025-11-13
- **Final completion:** 2025-11-13
- **Target enrollment:** 128 (ACTUAL)
- **Why stopped:** Sponsor decided to discontinue this study upon having LPLV.
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05012618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05012618, "A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05012618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*